Comparison
2p21 Microdeletion Syndrome C4304537 vs 11p15 4 Microduplication Syndrome C4749508
Clinical comparison between 2p21 Microdeletion Syndrome and 11p15 4 Microduplication Syndrome for differential diagnosis and treatment planning.
2p21 Microdeletion Syndrome C4304537
A rare genetic disorder involving deletion of genetic material on chromosome 2. It may affect multiple body systems and development. Management is tailored to individual symptoms.
11p15 4 Microduplication Syndrome C4749508
A rare genetic disorder involving duplication of material on chromosome 11, leading to varied developmental features. Requires individualized medical assessment.
6 comparison axes
Onset
2p21 Microdeletion Syndrome C4304537
0-null
11p15 4 Microduplication Syndrome C4749508
0-null
Onset patterns differ
Severity
2p21 Microdeletion Syndrome C4304537
severe
11p15 4 Microduplication Syndrome C4749508
moderate
Different severity levels
Chronic
2p21 Microdeletion Syndrome C4304537
Chronic
11p15 4 Microduplication Syndrome C4749508
Chronic
Differing course
Communicable
2p21 Microdeletion Syndrome C4304537
No
11p15 4 Microduplication Syndrome C4749508
No
Different transmission
Body System
2p21 Microdeletion Syndrome C4304537
congenital
11p15 4 Microduplication Syndrome C4749508
congenital
Same/different system
Category
2p21 Microdeletion Syndrome C4304537
rare-disease
11p15 4 Microduplication Syndrome C4749508
genetic
Different category
Bottom line
2p21-microdeletion-syndrome-C4304537 and 11p15-4-microduplication-syndrome-C4749508 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 2p21 Microdeletion Syndrome C4304537 | 11p15 4 Microduplication Syndrome C4749508 | Discriminating power |
|---|---|---|---|
| Developmental features | May involve multisystem developmental effects, but exact features are not established. | Described as varied developmental features without a defined pattern. | Low |
| Reported severity | Source severity is labeled severe. | Source severity is labeled moderate. | Moderate |
| Chromosomal change | Deletion of material on chromosome 2. | Duplication of material on chromosome 11. | High |
When to favor each condition
Choose 2p21 Microdeletion Syndrome C4304537 when
Confirmed chromosome 2 deletion
The defining distinction is deletion at 2p21, not clinical severity alone.
High
Multisystem congenital presentation
The source states multiple body systems and development may be affected.
Low
Need for individualized care planning
Management is described as tailored to individual symptoms.
Moderate
Choose 11p15 4 Microduplication Syndrome C4749508 when
Confirmed chromosome 11 duplication
Diagnosis depends on duplication involving 11p15.4.
High
Varied developmental findings
The source describes varied developmental features requiring assessment.
Low
Moderate source severity label
The supplied severity is moderate, but this does not establish prognosis.
Low
How key tests differ
| Test | 2p21 Microdeletion Syndrome C4304537 | 11p15 4 Microduplication Syndrome C4749508 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May identify a 2p21 deletion. | May identify an 11p15.4 duplication. | The copy-number result distinguishes the conditions; clinician review is required. |
| Confirmatory cytogenetic testing | Supports deletion when clinically indicated. | Supports duplication when clinically indicated. | Method and interpretation depend on the laboratory and clinical context. |
| Developmental assessment | May document multisystem developmental needs. | May document varied developmental needs. | Assessment characterizes impact but does not replace genetic confirmation. |
Prognosis comparison
2p21 Microdeletion Syndrome C4304537
- Outcome
- Long-term outcome is not established; source severity is severe.
- Factors
- Deletion extent, affected systems, and individual findings may matter.
11p15 4 Microduplication Syndrome C4749508
- Outcome
- Long-term outcome is not established; source severity is moderate.
- Factors
- Duplication extent and developmental findings may matter.
Time frame: Both are described as chronic, but onset data are incomplete.
Prognosis requires clinician interpretation of genetic and clinical findings.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impact | Possible, extent not established. Possible and described as varied. Neither source defines specific complications or their frequency. |
| Multisystem involvement | Explicitly possible. Not specifically established. Absence from the source does not exclude involvement. |
| Long-term medical needs | Likely individualized because of severe labeling. Likely individualized because features vary. No treatment doses, mortality, or complication rates are supplied. |
Patient education highlights
- HighGenetic confirmation
The chromosomal finding, not symptoms alone, distinguishes these rare conditions.
- HighIndividualized care
Management should follow the person's confirmed findings and clinician assessment.
- MediumEvidence limits
Available descriptions do not establish exact symptoms, onset, prognosis, or treatment.